Verified by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., July 2009 .
A randomized, multicenter, Phase III trial to evaluate the effectiveness of trabectedin versus standard doxorubicin-based chemotherapy (DXCT) as first-line treatment of patients with advanced TRS, by comparing progression-free survival (PFS) in the two treatment arms.
...